JOANNA REAVES: Open Payments
NPI 1487249470 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$978 in 58 payments from 14 companies in 2025. Trend: 2023 $669 · 2024 $1,252 · 2025 $978
Food & beverage: $978
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 9 | $176 |
| Dexcom, Inc. | 13 | $157 |
| PFIZER INC. | 7 | $119 |
| Astellas Pharma US Inc | 5 | $109 |
| Novo Nordisk Inc | 6 | $100 |
| Corcept Therapeutics | 5 | $95 |
| Lilly USA, LLC | 4 | $65 |
| AstraZeneca Pharmaceuticals LP | 3 | $49 |
| Abbott Laboratories | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
Products named: Dexcom G6 Transmitter, TRELEGY ELLIPTA, Veozah, Korlym, Ozempic, PREVNAR 20, FARXIGA, AREXVY.
Industry payments across AL — which companies pay providers there.
